Literature DB >> 21889983

Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model.

Yasumasa Yoshiyama1, Ayako Kojima, Kimiko Itoh, Tomoyuki Uchiyama, Kimihito Arai.   

Abstract

Anticholinergics, and drugs with anticholinergic properties, are widely and frequently prescribed, especially to the elderly. It is well known that these drugs decrease cognitive function and increase the risk of dementia. Although the mechanism of anticholinergic drug-induced cognitive impairment has been assumed to be functionally reduced acetylcholine (ACh) neurotransmission, some data have indicated that anticholinergics might enhance the pathology of Alzheimer's disease. In this study, we investigated the pathological effects of anticholinergics on neurodegeneration. We chronically administered two anticholinergics, trihexyphenidyl (TP) and propiverine (PP) (the latter with less central anticholinergic action), to neurodegenerative tauopathy model mice 2 to 10 months old. Furthermore, because the ACh nervous system regulates both central and peripheral inflammation, we administered TP or PP to PS19 mice in which we had artificially induced inflammation by lipopolysaccharide injection. Tau pathology, synaptic loss, and neurodegeneration in the hippocampal region, as well as tau insolubility and phosphorylation, were markedly increased in TP-treated mice and mildly increased in PP-treated mice. Furthermore, immunohistochemical analysis revealed microglial proliferation and activation. Moreover, anticholinergics increased interleukin-1β expression in both the spleen and brain of the tauopathy model mice intraperitoneally injected with lipopolysaccharide to induce systemic inflammation. Interestingly, these alterations were more strongly observed in TP-treated mice than in PP-treated mice, consistent with the level of central anticholinergic action. Anticholinergic drugs not only impair cognitive function by decreased ACh neurotransmission, but also accelerate neurodegeneration by suppressing an ACh-dependent anti-inflammatory system. Anticholinergics should be less readily prescribed to reduce the risk of dementia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889983     DOI: 10.1016/j.nbd.2011.08.017

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  12 in total

Review 1.  Neural circuitry and immunity.

Authors:  Valentin A Pavlov; Kevin J Tracey
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

2.  Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort.

Authors:  Shelly L Gray; Melissa L Anderson; Joseph T Hanlon; Sascha Dublin; Rod L Walker; Rebecca A Hubbard; Onchee Yu; Thomas J Montine; Paul K Crane; Josh A Sonnen; C Dirk Keene; Eric B Larson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women.

Authors:  Leah H Rubin; Kendra K Radtke; Seenae Eum; Bani Tamraz; Krithika N Kumanan; Gayle Springer; Pauline M Maki; Kathryn Anastos; Daniel Merenstein; Roksana Karim; Kathleen M Weber; Deborah Gustafson; Ruth M Greenblatt; Jeffrey R Bishop
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

Review 4.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 5.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

6.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

7.  Anticholinergic Drug Induced Cognitive and Physical Impairment: Results from the InCHIANTI Study.

Authors:  Lana Sargent; Mike Nalls; Elaine J Amella; Martina Mueller; Sarah K Lageman; Stefania Bandinelli; Marco Colpo; Patricia W Slattum; Andrew Singleton; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-04-17       Impact factor: 6.053

8.  Anticholinergic/sedative drug burden predicts worse memory acquisition in older racially/ethnically diverse patients with type 2 diabetes mellitus.

Authors:  Seth A Margolis; Malka Zughaft Sears; Lori A Daiello; Carly Solon; Luba Nakhutina; Claire J Hoogendoorn; Jeffrey S Gonzalez
Journal:  Int J Geriatr Psychiatry       Date:  2019-07-22       Impact factor: 3.485

9.  Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research.

Authors:  Harry Wu; John Mach; Danijela Gnjidic; Vasi Naganathan; Fiona M Blyth; Louise M Waite; David J Handelsman; David G Le Couteur; Sarah N Hilmer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-07-05       Impact factor: 6.591

Review 10.  Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs.

Authors:  Leonardo Guzmán-Martinez; Gonzalo A Farías; Ricardo Benjamin Maccioni
Journal:  Front Neurol       Date:  2013-10-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.